Thanks for the insight. That would make it easier yet. No ANDA required, start a subsidiary and start selling as generic albeit authorized generic.
Point being that JT should be drawing the market's attention to alternative paths to success should the appeal fail and should they have to compete with generics in the US.
North had pointed out that JT did mentioned it in one of his Conference Calls. I must have missed it and I pay fairly close attention.